Pneumocystis jirovecii pneumonia in adults without HIV infection: diagnostic uncertainty, treatment-limiting toxicity, and individualized management

Contemporary immunosuppressive and anticancer therapies have broadened the population at risk of developing Pneumocystis pneumonia (PCP) among adults without HIV. Compared with HIV-associated PCP, disease in this population is characterized by a lower organism burden with more rapid hypoxemic deterioration, and host comorbidities and concurrent therapies may limit treatment tolerance. This focused narrative review addresses three linked problems: diagnostic uncertainty, treatment-limiting toxicity, and individualized management. Diagnosis requires assessment of the probability rather than binary interpretation as present or absent based on Pneumocystis detection, integrating immune trajectory and prophylaxis received with imaging and oxygenation, specimen adequacy, PCR results, serum β-D-glucan, and competing diagnoses. Trimethoprim/sulfamethoxazole remains the first-line therapy, but organ dysfunction and treatment-emergent toxicity may prevent completion of treatment. Reduced-dose strategies may improve tolerability but are not established as a universal replacement for conventional dosing; apparent treatment failure should prompt reassessment of the working diagnosis and evaluation for co-infection. Current evidence does not support routine use of adjunctive corticosteroids for all patients. Selective use may be considered when evidence of PCP is strong, acute hypoxemic respiratory failure is present and competing causes of deterioration have been assessed. Primary and secondary prophylaxis should be reassessed as immune status, treatment phase, and tolerance evolve. A structured, standards-based approach applied at treatment initiation, early reassessment, and treatment completion or discharge, provides a practical framework for individualized care.

Authors

Institutions

Publication Details

Journal
Respiratory Investigation
Published
2026-11-18
DOI
https://doi.org/10.1016/j.resinv.2026.101541
Primary Topic
Pneumocystis jirovecii pneumonia detection and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pneumocystis jirovecii pneumonia in adults without HIV infection: diagnostic uncertainty, treatment-limiting toxicity, and individualized management

Kei Nakashima, Shin‐ichiro Ohmura
Respiratory Investigation
Pneumocystis jirovecii pneumonia detection and treatment
article

Pneumocystis jirovecii pneumonia in adults without HIV infection: diagnostic uncertainty, treatment-limiting toxicity, and individualized management

Kei Nakashima, Shin‐ichiro Ohmura
article en

Abstract

Contemporary immunosuppressive and anticancer therapies have broadened the population at risk of developing Pneumocystis pneumonia (PCP) among adults without HIV. Compared with HIV-associated PCP, disease in this population is characterized by a lower organism burden with more rapid hypoxemic deterioration, and host comorbidities and concurrent therapies may limit treatment tolerance. This focused narrative review addresses three linked problems: diagnostic uncertainty, treatment-limiting toxicity, and individualized management. Diagnosis requires assessment of the probability rather than binary interpretation as present or absent based on Pneumocystis detection, integrating immune trajectory and prophylaxis received with imaging and oxygenation, specimen adequacy, PCR results, serum β-D-glucan, and competing diagnoses. Trimethoprim/sulfamethoxazole remains the first-line therapy, but organ dysfunction and treatment-emergent toxicity may prevent completion of treatment. Reduced-dose strategies may improve tolerability but are not established as a universal replacement for conventional dosing; apparent treatment failure should prompt reassessment of the working diagnosis and evaluation for co-infection. Current evidence does not support routine use of adjunctive corticosteroids for all patients. Selective use may be considered when evidence of PCP is strong, acute hypoxemic respiratory failure is present and competing causes of deterioration have been assessed. Primary and secondary prophylaxis should be reassessed as immune status, treatment phase, and tolerance evolve. A structured, standards-based approach applied at treatment initiation, early reassessment, and treatment completion or discharge, provides a practical framework for individualized care.

Respiratory InvestigationVol. 65(1)
Kameda Medical Center (JP), Seirei Hamamatsu General Hospital (JP)
Pneumocystis jirovecii pneumonia detection and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon